Keebeck Wealth Management Buys New Holdings in Bristol Myers Squibb Company $BMY

Key Points

• Keebeck Wealth Management purchased 16,581 Bristol Myers Squibb shares worth approximately $955,000 in the second quarter, while institutional investors overall own 76.41% of BMY.
• Bristol Myers Squibb reported quarterly EPS of $2.04, beating estimates of $1.60, while revenue rose 5.7% year over year to $12.97 billion. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $66.06.
• BMY pays an annualized dividend of $2.52 per share, yielding about 3.8%; however, generic competition affecting older products remains a key risk despite Eliquis strength and ongoing pipeline investments.

Keebeck Wealth Management purchased a new position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 16,581 shares of the biopharmaceutical company's stock, valued at approximately $955,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BMY. Swiss RE Ltd. bought a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $25,000. Darwin Wealth Management LLC bought a new position in shares of Bristol Myers Squibb during the second quarter worth $25,000. Physician Wealth Advisors Inc. grew its stake in Bristol Myers Squibb by 73.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 202 shares in the last quarter. Bayban bought a new stake in Bristol Myers Squibb in the 4th quarter valued at $31,000. Finally, EQ Wealth Advisors LLC purchased a new stake in Bristol Myers Squibb in the 4th quarter worth $32,000. 76.41% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Weiss Ratings raised shares of Bristol Myers Squibb from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday. Raymond James Financial started coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a "strong-buy" rating on the stock. Wells Fargo & Company set a $65.00 price target on Bristol Myers Squibb and gave the company an "equal weight" rating in a research note on Friday, July 31st. Piper Sandler assumed coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set an "overweight" rating for the company. Finally, Jefferies Financial Group downgraded Bristol Myers Squibb from a "buy" rating to a "hold" rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $66.06.

Bristol Myers Squibb Stock Performance

Shares of NYSE:BMY opened at $67.06 on Friday. The firm has a fifty day simple moving average of $60.55 and a two-hundred day simple moving average of $59.37. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The stock has a market capitalization of $136.98 billion, a P/E ratio of 14.77, a PEG ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm had revenue of $12.97 billion for the quarter, compared to analysts' expectations of $11.74 billion. During the same period in the prior year, the company earned $1.46 EPS. The business's revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, analysts expect that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were given a dividend of $0.63 per share. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 3.8%. Bristol Myers Squibb's dividend payout ratio is 55.51%.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb plans to invest approximately $2.3 billion in a new Houston manufacturing facility, part of a broader $40 billion U.S. investment commitment. The project reinforces BMY’s confidence in domestic production capacity and could support long-term operational growth. Bristol-Myers Squibb Bets $2.3 Billion on Texas
• Positive Sentiment: BMY is collaborating with Chai Discovery on artificial-intelligence-driven antibody discovery. The partnership could help identify novel therapeutic candidates more efficiently and strengthens the company’s efforts to modernize its drug-development platform. Chai Discovery Collaboration
• Positive Sentiment: The company is launching a Phase 1 study of an early Alzheimer’s disease antibody. Although the program remains highly experimental, it adds another potential long-term growth opportunity to BMY’s pipeline. Early Alzheimer’s Antibody Study
• Positive Sentiment: Strong Eliquis performance is helping offset declines in BMY’s older products facing generic pressure, supporting a more favorable 2026 revenue outlook. Elevated call-option activity also signals increased bullish interest, though it is not a fundamental guarantee. Eliquis and Legacy Portfolio Analysis
• Neutral Sentiment: Early clinical work on navlimetostat shows continued pipeline activity, but the Phase 1-stage program has not yet produced efficacy data that would materially change near-term earnings expectations. Navlimetostat Study Update
• Negative Sentiment: Generic competition remains a key risk for BMY’s legacy portfolio. Investors must determine whether Eliquis growth and newer pipeline assets can replace revenue lost as established medicines face erosion. Legacy Portfolio Erosion Analysis

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source